Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →BioSpace reported the headline ~$446M / €314M cash + ~€50M assumed debt structure and 87.2% controlling-stake mechanic, characterizing the deal as a tactical…
PharmaTimes highlighted that Sanitas's projected 2011 revenue >€100M and low double-digit growth gave Valeant an immediately accretive CEE platform with…
Canadian financial press positioned the deal as Valeant's first significant move after losing the Cephalon contest to Teva — a smaller, geography-fill…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Valeant acquired 87.2% of Lithuanian/CEE pharma group Sanitas for €314M (~$440M).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / Sanitas (this deal) | 2011 | $440M | — |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
← Browse all deals · How we score deals
More: 2011 deals · Valeant Pharmaceuticals International, Inc. deals · Other deals